로딩 중…
지수 로딩 중…
HLB bioStep Co.,Ltd.
278650· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩6,870+29.87%
2026-11-02
Financials
Valuation Metrics
HLB bioStep Co.,Ltd.'s Market Cap is ₩1198B. At end of 2025 it was ₩1267B. Ranked #1110 of 2,405 in KR market (top 46%), #575 of 1,627 on KOSDAQ (top 35%), #129 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 56%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 119.76B KRW | KR#1,110/2,405 Sec#129/231 |
| Revenue | 72.15B KRW | KR#1,600/2,405 Sec#105/231 |
| Net Income | -19.48B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 145.77B KRW | KR#1,522/2,405 Sec#114/231 |
| Net Assets | 96.61B KRW | KR#1,443/2,405 Sec#114/231 |
| Employees | 167 | KR#1,226/2,405 Sec#101/231 |
| Value | ||
| P/B | 1.24x | KR#1,697/2,405 Sec#113/231 |
| P/S | 1.66x | KR#1,753/2,405 Sec#100/231 |
| FCF Yield | 0.93% | KR#1,145/2,405 Sec#85/231 |
| Profitability | ||
| ROE | -20.17% | KR#2,087/2,405 Sec#163/231 |
| ROA | -13.37% | KR#2,155/2,405 Sec#166/231 |
| Op. Margin | -8.68% | KR#1,950/2,405 Sec#133/231 |
| Revenue Growth | 9.27% | KR#935/2,405 Sec#92/231 |
| Financial Health | ||
| Debt Ratio | 50.88% | KR#966/2,405 Sec#112/231 |
| Total Debt | 30.11B KRW | KR#1,223/2,405 Sec#95/231 |
| FCF | 1.11B KRW | KR#1,137/2,405 Sec#83/231 |
| Cash | 33.32B KRW | KR#943/2,405 Sec#62/231 |
| Current Ratio | 1.27x | KR#1,416/2,405 Sec#150/231 |
| Dividend | ||
| Div. Growth | 35.17% | KR#320/2,405 Sec#16/231 |
| Performance | ||
| 1Y Return | 11.71% | KR#402/2,405 Sec#24/231 |
| 1M Return | 138.96% | KR#2/2,405 Sec#1/231 |
| From 52W High | -31.98% | KR#470/2,405 Sec#31/231 |
| 1Y MDD | -80.97% | KR#2,292/2,405 Sec#205/231 |
| Trading | ||
| Volume | 3,190,511 shares | KR#24/2,405 Sec#1/231 |
| Trading Value | 20.35B KRW | KR#111/2,405 Sec#5/231 |
| Foreign Own. | 0.52% | KR#2,192/2,405 Sec#211/231 |
| Per Share | ||
| EPS | -1,118 KRW | KR—/2,405 Sec—/231 |
| BPS | 5,542 KRW | KR#1,426/2,405 Sec#103/231 |
Company Info
동사는 2012년 설립된 비임상 CRO 전문기업으로 코스닥 상장 후 2024년 GLP 독성시험 전문기업 HLB바이오코드를 인수하여 종속회사로 편입함. 신약 후보물질의 유효성과 안전성 검증을 주력으로, HLB바이오코드 인수로 GLP 독성시험까지 원스톱 서비스 제공이 가능해짐. 질환동물 유발 및 관리 특화 기술력으로 중대동물 실험에서 독보적 지위 확보, HLB그룹과 AI 신약개발 플랫폼 구축 등 신사업을 추진하고 있음. HLB바이오스텝는 2012년에 설립되었으며 인천광역시 연수구에 본사를 두고 있습니다.